6
Jun
2022
Aripiprazole
Posted On June 6, 2022
By Dr.Adel Serag
And has No Comment
Aripiprazole (Abilify, BMS) (Aripix, Zolinda, Aripiprex) is a second-generation antipsychotic approved in 2002 for the treatment of schizophrenia. Oral and intramuscular formulations are available. This page summarizes the FDA-approved use of aripiprazole for the management of schizophrenia. Also the Off label use, how it works, and its pharmacokinetics.
FDA approved indication for Aripiprazole
How it works
PharmacoKinetics:
Aripiprazole and Schizophrenia
- Aripiprazole is a partial agonist at D2 receptors.
- It may act as an antipsychotic by:
- Lowering dopaminergic neurotransmission in the mesolimbic pathway.
- Enhancing dopaminergic activity in the mesocortical pathway.
- It has a lower risk of EPS and hyperprolactinemia than other antipsychotics.
Positive symptoms of schizophrenia might be the result of the overactivation of the mesolimbic pathway.
One postulated mechanism of action of aripiprazole in schizophrenia is the ability of the drug to increase dopaminergic activity from a subnormal level to normal activity in the mesocortical pathway.
Aripiprazole reduces dopaminergic activity in the mesolimbic pathway through partial D2 agonism.
